What happened in optometry this week: October 28 - November 1
Catch up on what happened in optometry during the week of October 28-November 1.
Catch up with what Optometry Times shared this week:
CORXEL and LENZ Therapeutics announce positive topline data from China phase 3 presbyopia trial of LNZ100
By Lynda Charters
Corxel Pharmaceuticals (CORXEL) and LENZ Therapeutics released positive topline data from the phase 3 JX07001 clinical trial of LNZ100 (1.75% aceclidine HCl, a miotic) in presbyopic Chinese patients.
The phase 3 safety and efficacy results showed that the drug met the primary endpoint and key secondary endpoints, with 3 lines or more improvements in the best-corrected distance visual acuity (VA) at near and the patients maintained their optimal distance VA, defined as no loss of 5 or more letters, according to a press release.
Contact Lens Institute releases full report on contact lens wearer retention
By Jordana Joy, Associate Editor
Following consumer data released in late September,1 the Contact Len Institute (CLI) has released the full report that detailed new and long-term soft contact users’ rates of retention. The report, entitled “Disrupting the Dropout Dilemma: Practical Steps to Keep Patients in Contact Lenses,” found that satisfaction in contact lens wear was generally high across all survey participants.2
A model to predict iris melanoma
By Lynda Charters
Arun Singh, MD, and colleagues developed a model that provides direct diagnostic prediction of a lesion being iris melanoma.1 He is Director of the Department of Ophthalmic Oncology, Cole Eye Institute at the Cleveland Clinic, Cleveland Clinic Main Campus Hospital, Cleveland.
The investigators conducted a retrospective consecutive case series that included 100 cases of pathologically confirmed iris melanoma and 112 cases of iris naevus, with either pathological confirmation or documented stability exceeding 1 year.
AAOpt 2024: AAO-sponsored report recommends a disease classification for myopia
By Jordana Joy, Associate Editor
The American Academy of Optometry has sponsored a National Academies of Sciences, Engineering, and Medicine (NASEM) that has recommended that the Centers for Medicare and Medicaid Services classify myopia as a disease.1 The report, entitled “Myopia: Causes, Prevention, and Treatment of an Increasingly Common Disease,” compiled from a consensus study, works to identify and assess the current mechanistic understanding of myopia pathogenesis and the causes of its increased prevalence.
Cutting back on screen time for the sake of myopia management
By Erin Tomiyama, OD, PhD, FAAO
In an increasingly digital world, the rise of myopia has become a significant concern. Although it is easy to assume there is a direct connection between screen time and the myopia epidemic, the prevalence of myopia has been on the rise long before the increased use of screen time in children. In the early 2000s, the prevalence of myopia was almost double that in the 1970s.1 Despite this observation, myopia development is multifactorial, thus the relationship between screen time and myopia must be explored.
